Steg, P.G., Harrington, R.A., Emanuelsson, H., Katus, H.A., Mahaffey, K.W., Meier, B., et al. (2013) Stent thrombosis with ticagrelor versus clopidogrel in patients with acute co-ronary syndromes: An analysis from the prospective, randomized PLATO trial. Circulation, 128, 1055-1065.
阿托伐他汀联合替格瑞洛治疗急性冠脉综合症介入术后患者两种药物临床疗效的相互影响The Mutual Effect of Clinical Efficacy of Atorvastatin Combined with Ticagrelor for Patients with Acute Coronary Syndrome after Interventional Treatment
宋剑, 刘美莲, 朱王亮, 陈丽珠, 李莉, 郑玉云
替格瑞洛, 阿托伐他汀, 急性冠脉综合症, 药物相互作用Ticagrelor, Atorvastatin, Acute Coronary Syndrome, Drug Interaction
《Advances in Clinical Medicine》, Vol.5 No.3, 2015-09-24
Objective: To explore the clinical effects and side effect of atorvastatin combined with ticagrelor for patients with acute coronary syndrome after interventional treatment. Methods: 120 cases of hospitalized patients in our Department of Cardiology of 2014 was collected, according to the clinical symptoms and coronary angiography in the diagnosis of acute coronary syndrome (ACS), the selected patients were randomly divided into the atorvastatin clopidogrel group and atorvastatin for Greg groups, we measured serum uric acid, transaminase, creatine kinase, platelet aggregation rate, lipid levels, etc. of the patients and compared whether there was influence of the clinical curative effect on each other. Results: There were significant differences between clopidogrel group and Greg los group in blood platelet aggregation rate (P 0.05). Conclusions: Studies have shown competitive inhibition of CYP3A4 between atorvastatin and ticagrelor, resulting in certain influence on the pharmacokinetics, however, their clinical efficacy showed no significant change in the short term when used in combination.